Showing results (211-220 of 651) with videos related to
Sort By:
Pageof 66
Presse Medicale (Paris, France : 1983)|December 10, 1999
[Type 1 diabetes mellitus]E Larger, D Dubois-Laforgue, J TimsitClinical Pharmacokinetics|November 1, 1993
Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumoursP Chanson, J Timsit, A G HarrisDiabetes & Metabolism|September 30, 2000
[Is diabetes mellitus a sufficient condition to suspect hemochromatosis?]D Dubois-Laforgue, E Larger, J TimsitAnnals of the New York Academy of Sciences|February 28, 1975
Regulation of theta-antigen expression by agents altering cyclic AMP level and by thymic factorM A Bach, C Fournier, J F BachEuropean Journal of Immunology|February 1, 1980
Evidence of the presence in normal serum of a carrier of the serum thymic factor (FTS)M Dardenne, J M Pléau, J F BachJournal of Autoimmunity|April 1, 1992
Epstein-Barr virus serology and isoelectrofocusing pattern of serum immunoglobulins in cyclosporin or placebo-treated type I diabeticsG Feutren, G de The, J F BachHuman Immunology|July 31, 1998
HLA class II-associated predisposition to insulin-dependent diabetes mellitus in a Polish populationM Krokowski, J Bodalski, A Bratek, et al.Presse Medicale (Paris, France : 1983)|December 18, 1993
[Octreotide, analog of somatostatin. Pharmacological properties and therapeutic applications in pituitary endocrine tumors]P Chanson, J Timsit, A G HarrisGenomics|June 2, 2001
Three loci on mouse chromosome 6 influence onset and final incidence of type I diabetes in NOD.C3H congenic strainsU C Rogner, C Boitard, J Morin, et al.European Journal of Immunology|June 1, 1995
Lack of L-selectin expression by cells transferring diabetes in NOD mice: insights into the mechanisms involved in diabetes prevention by Mel-14 antibody treatmentF Lepault, M C Gagnerault, C Faveeuw, et al.Pageof 66